Welcome to our dedicated page for Cellebrite Di SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellebrite’s blend of recurring SaaS licenses, hardware sales, and multi-year law-enforcement contracts fills its SEC documents with segment tables, backlog metrics, and privacy-risk footnotes that can run well past 250 pages. Hunting for the exact numbers—or the latest insider trades—often feels like a forensic job of its own.
That’s why this page pairs every submission with Stock Titan’s AI-powered summaries. Need the «Cellebrite insider trading Form 4 transactions» or alerts on «Cellebrite Form 4 insider transactions real-time»? They’re surfaced instantly. Curious how revenue shifted in the «Cellebrite quarterly earnings report 10-Q filing» or want the big picture from the «Cellebrite annual report 10-K simplified»? One click delivers a plain-English brief, ratio analysis, and red-flag highlights. Our engine also tags «Cellebrite proxy statement executive compensation», breaks down option grants, and decodes «Cellebrite 8-K material events explained» within minutes.
Investors use these tools to compare recurring-revenue retention, monitor «Cellebrite executive stock transactions Form 4», and spot contract wins disclosed between quarters. The result: «understanding Cellebrite SEC documents with AI» becomes practical. From cash-flow insights in a 10-K to risk updates in an 8-K, every «Cellebrite earnings report filing analysis» is updated in real time and grouped alongside historical filings for trend tracking. No more scrolling through EDGAR—just the answers you need, when you need them.
Form 144 notice shows a proposed sale of 25,390 common shares of Cellebrite DI Ltd. (CLBT) through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of
The securities listed were mainly acquired under the issuer’s registered plans: two lots of 4,829 shares each from option exercises on
Cellebrite DI Ltd. (CLBT) Form 144 shows a proposed sale of 508,790 common shares, with an aggregate market value of $9,366,104.61, to be sold on or about 09/24/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing breaks out how the shares were acquired: 10,373 shares from restricted stock dated 09/17/2025 and 498,417 shares from a stock option exercise on 09/24/2025 paid in cash. It also discloses a recent sale of 6,847 shares on 09/02/2025 for gross proceeds of $112,016.92. The filer attests there is no undisclosed material adverse information.
Form 144 filing for Cellebrite DI Ltd. (CLBT) reports a proposed sale of 40,535 common shares held as restricted stock units acquired on 02/15/2023. The filing lists Morgan Stanley Smith Barney LLC as the broker and an approximate aggregate market value of $728,413.95 with an expected sale date of 09/23/2025 on NASDAQ. The filer represents they are unaware of any undisclosed material adverse information. The filing also discloses 10b5-1 sales executed on 09/22/2025 totaling 25,810 shares for gross proceeds of $464,610.97. The issuer’s total shares outstanding are stated as 244,469,106.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $601,399.11 and 245,691,023 shares outstanding. The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd. and were received as compensation. The filing indicates no reported sales by the seller in the past three months. Several filer identification fields in the public extract (CIK/CCC and contact details) are blank in the provided text.
Form 144 notice for proposed sale of securities by an insider or affiliate. The filing reports an intended sale of 25,810 shares of Common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $454,514.10. The shares are listed on NASDAQ and the approximate sale date provided is 09/22/2025. The shares were acquired as restricted stock units from the issuer on 02/15/2023, and no related securities sales were reported in the prior three months. Several filer and issuer identification fields are left blank in the supplied content.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.
FAQ
What is the current stock price of Cellebrite Di (CLBT)?
What is the market cap of Cellebrite Di (CLBT)?
